Integer Holdings Corp(ITGR)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Integer Holdings Corp (ITGR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ITGR at 55.9/100 on a 32-signal composite quality model, placing it at rank #1,217 of 2,961 stocks — the top half of the AI-ranked universe. ITGR scores in the top quartile across earnings quality (76.7). Areas of concern include institutional flow (25.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Integer Holdings Corp reports quarterly revenue of $464.1M, net income of $23.6M, an operating margin of 7.4%. Top institutional holders of ITGR by reported 13-F value include BlackRock, Invesco Ltd., VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ITGR trades on the NYSE exchange and files with the SEC under CIK 1114483. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ITGR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Integer Holdings Corp directly from SEC EDGAR.
AI Quality Score
55.9/100
AI Rank
#1,217
Revenue
$464.1M
Net Income
$23.6M
Free Cash Flow
$37.0M
Operating Margin
7.4%
ITGR key financials by period
Integer Holdings Corp reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.9B
$102.8M
11.9%
FY 2024
10-K
$1.7B
$119.9M
12.1%
FY 2023
10-K
$1.6B
$90.7M
10.5%
FY 2022
10-K
$1.3B
$66.4M
8.5%
FY 2021
10-K
$1.2B
$96.8M
11.1%
FY 2020
10-K
$1.1B
$77.3M
11.2%
Institutions holding ITGR
Institutional investors reporting a position in Integer Holdings Corp on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended July 3, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Integer Holdings reported Q2 2026 revenue of $464.1M, down 2.6% YoY, with operating income declining 41.8% to $34.5M due to lower fixed cost absorption and three new products underperforming market adoption expectations.
Biggest Revenue Drivers
Cardio & Vascular$280.3M-2.3% YoY
Lower sales of two new Electrophysiology products due to lower than anticipated market adoption, partially offset by 2025 acquisitions.
Growth partially offset by lower sales of a Neuromodulation product due to lower than anticipated market adoption.
Other Markets$10.1M-42.8% YoY
Decline primarily due to the Portable Medical Exit.
Largest Expense Items
Cost of sales$351.2M+1.1% YoY
Increased primarily due to lower fixed cost absorption from lower production volumes.
Selling, general and administrative$57.7M+9.0% YoY
Higher professional fees for stockholder activist matter and securities class action lawsuit defense; higher contract services for IT enhancements.
Restructuring and other charges$9.4M+256.0% YoY
$5.9M fixed asset impairment from revised expectations on future use of certain assets; higher restructuring charges.
Research, development and engineering$11.3M-20.8% YoY
Decrease primarily due to timing of program milestone achievements for customer funded programs.
Watch Items from the Filing
Three significant new products experienced lower than anticipated market adoption in Q2 2026, impacting sales and requiring reassessment of growth strategy.
Customer concentration: Customer A represents 18%, Customer B 17%, and Customer C 17% of Q2 2026 revenue; top three customers represent 52% of sales.
On August 2, 2026, Integer agreed to be acquired by KKR affiliates for $127 per share; pending stockholder approval and regulatory clearance with outside date of May 2, 2027.
Fixed asset impairment charge of $5.9M in Q2 2026 reflects revised expectations on future use of manufacturing equipment and reduced recovery confidence.
Gross margin pressure continues; company expects gross margin to fluctuate but has not provided recovery timeline for the 280 bps decline.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
